Palisade Bio Inc. Stock
Price
Target price
-
-
-
-
-
?14.40
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Palisade Bio Inc. Stock
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Palisade Bio Inc..
Based on the current price of 0.34 € the target price of 14 € shows a potential of 4003.17% for Palisade Bio Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Palisade Bio Inc. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.990% | 2.000% | 13.966% | 14.607% | 10.270% | -53.846% | -58.197% |
| Rockwell Medical Inc. | 0.240% | -0.762% | -1.969% | -58.300% | -58.011% | -14.925% | -92.025% |
| Twist Bioscience Corp | -0.750% | 0.653% | 6.119% | -44.411% | -39.318% | 15.217% | -74.541% |
Comments
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen to a "sell" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
